Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb 15:263:258-266.
doi: 10.1016/j.jad.2019.11.074. Epub 2019 Nov 13.

Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma

Michael Cronquist Christensen  1 , Ioana Florea  2 , Henrik Loft  2 , Roger S McIntyre  3
Affiliations
Free article
Randomized Controlled Trial

Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma

Michael Cronquist Christensen et al. J Affect Disord. .
Free article

Abstract

Background: This analysis investigates the efficacy of vortioxetine in adults with major depressive disorder (MDD) who report childhood or recent trauma.

Methods: Patient-level data were analyzed from 4 double-blind, randomized, placebo-controlled short-term studies investigating the efficacy of vortioxetine (5-20 mg/day) versus placebo in patients (18-75 years old) with DSM-IV-TR-defined MDD. Changes from baseline to week 8 on the Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression - Improvement (CGI-I), and Sheehan Disability Scale (SDS) were examined at the individual study level and as in meta-analysis. A long-term relapse prevention study of 5 and 10 mg of vortioxetine was also analyzed. Traumatic events history was recorded at baseline.

Results: Sixty-one percent of subjects (1113/1811) reported trauma history in the short-term studies. A significant effect vs. placebo was observed for vortioxetine on MADRS (10 mg, -2.2, P = .025; 20 mg, -4.4, P < .001), HAM-A (20 mg, -1.60, P = .012), CGI-I (5 mg, -0.3, P = .028; 10 mg, -0.3, P = .013; 20 mg, -0.50, P = .009), and SDS (20 mg, -2.3, P = .007) in patients with any trauma (childhood and/or recent). In the relapse prevention study, 51% (198/392) of subjects reported a history of trauma. Subjects with any trauma (childhood and/or recent) randomized to placebo were significantly more likely to relapse than subjects treated with vortioxetine (hazard ratio 2.8, P = .0019).

Limitations: An exploratory analysis.

Discussion: Vortioxetine showed significant short- and long-term efficacy on depressive and anxiety symptoms and overall functioning in this large subpopulation of MDD patients with a history of trauma. A significantly lower risk of relapse was also observed with vortioxetine.

Trial registration: ClinicalTrials.gov NCT01153009 NCT00635219 NCT01163266 NCT01140906 NCT00596817.

Keywords: Anxiety; Childhood; Depression; Functioning; Trauma; Vortioxetine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Drs Christensen, Florea, and Loft are employees of H. Lundbeck A/S. Dr. McIntyre has received research grants from the following private industries or nonprofit funds: Stanley Medical Research Institute, National Alliance for Research on Schizophrenia and Depression (NARSAD), and National Institutes of Mental Health. During the past 3 years, Dr McIntyre has received fees for speaking/consultation from Shire, Purdue, Otsuka, Janssen-Ortho, Lundbeck, Pfizer, Neurocrine, Neuralstem, Sunovion, Takeda, and Allergan and research support from Lundbeck, Shire, Purdue, and Allergan. Dr. McIntyre has not received any financial support from H. Lundbeck A/S or other sources for the research presented in this manuscript.

Publication types

Associated data

LinkOut - more resources